Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia

NCT04714593 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphocytic Leukemia， B-Cell

Interventions

BIOLOGICAL: CD19-CD22 CAR-T cells

Sponsor

Shanxi Province Cancer Hospital

Collaborators

[object Object]